ImmuPharma (LON:IMM) Trading Up 20.6% – Here’s What Happened

ImmuPharma plc (LON:IMM) was up 20.6% during trading on Friday . The company traded as high as GBX 13.19 ($0.18) and last traded at GBX 13.08 ($0.18). Approximately 27,867,863 shares traded hands during trading, an increase of 247% from the average daily volume of 8,024,198 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Trading Up 28.8%

The stock has a market capitalization of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53. The business has a 50-day moving average price of GBX 3.12 and a 200 day moving average price of GBX 2.92.

ImmuPharma (LON:IMM) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, sell-side analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.